[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617913":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":44,"collaborators":20,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":20,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental arm","EXPERIMENTAL","Pts will receive adaptive boost for clinically significant disease",[13],"Radiation: adaptive RT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","adaptive RT","Prostate cancer pts post-prostatectomy：95%PTVboost 7Gy\u002F3.5Gy\u002F2f，95%PTV 66Gy\u002F2.0Gy\u002F33f，w\u002Fo 95%PTVp 50Gy\u002F2.0Gy\u002F25f Bladder cancer pts with bladder-conserving txt：95%PGTV 18Gy\u002F6.0Gy\u002F3f，95%PTV 50Gy\u002F2.0Gy\u002F25f，w\u002Fo 95%PTVp 50Gy\u002F2.0Gy\u002F25f",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Ning-Ning Lu, M.D.","CONTACT","861018611804268","ningninglu09@163.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Cancer Hospital, National Cancer Center, CAMS & PUMC","RECRUITING","Beijing","Beijing Municipality","100021","China","CN",{"type":37,"coordinates":38},"Point",[39,40],116.39723,39.9075,{"lat":40,"lon":39},[43],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","NINGNING LU","Principal Investigator","100617913","adaptive-radiotherapy-for-genitourinary-cancers-100617913",false,"NCT07324798","Adaptive Radiotherapy for Genitourinary Cancers","Prospective Study of siMultaneous Adaptive RadioTherapy for Local Boost for Prostate and Bladder Cancers (SMART-B01)","SMART-B01","Inclusion Criteria:\n\n* Patients with newly diagnosed or metastatic\u002Frecurrent pathologically confirmed urological tumors, clinically assessed as suitable for adaptive radiotherapy;\n* Age ≥ 18 years;\n* ECOG performance status score 0-2;\n* No prior radiotherapy history within the current radiation field;\n* No contraindications for MRI scanning;\n* No contraindications for radiotherapy.\n\nExclusion Criteria:\n\n* Patients with contraindications to radiotherapy;\n* Patients unable to tolerate MRI or with contraindications to MRI scanning.","MALE","18 Years",{"count":59,"type":60},60,"ESTIMATED","INTERVENTIONAL",[63],"NA","The goal of this clinical trial is to learn if adaptive radiation boost works to treat genitourinary cancers, esp. in the context of prostate cancer patients with post-prostatectomy local relapse and bladder cancer patients with bladder-conserving treatment. It will also learn about the safety and efficacy of adaptive boost. The main questions it aims to answer are:\n\nDoes adaptive boost lower the toxicities? Does adaptive boost maintain or improve the clinical efficacy?\n\nParticipants will:\n\nUndergo adaptive boost on 1.5-Tesla MR-Linac Visit the clinic once every 2 weeks during RT, and every 3 months post-ART Keep a regular QOL questinnaire completion",[66,67],"Prostate Cancer (Post Prostatectomy)","Bladder Cancer",[69,70,71,72,73],"prostate cancer","bladder cancer","adaptive radiotherapy","post-prostatectomy","bladder-conserving treatment","2025-12-29",{"date":76,"type":77},"2026-01-07","ACTUAL",{"date":79,"type":77},"2024-12-01",{"date":81,"type":60},"2028-12-31",{"name":5,"class":6},1]